Notable Labs Analysis

The Business Model Canvas

Key Partners

  • "Pharma Partners 50% revenue growth over 2017 at the close of Q3 with many additional projects set to close ** Four of the top ten pharma companies in the world are now working with Notable! ** Other customer traction: +15 publicly traded biotech and private company partners

Key Activities

  • Notable Labs which has developed a personalized treatment service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor.
  • Notable pitched its ability to add value to assets stalled in clinical trials through patient selection, which would increase clinical trial response rates and identification of novel drug combinations. Notable’s business development team is actively negotiating with pharma and biotech companies on in-licensing candidates.

Value Proposition

  • As you know, Notable’s mission has always been to advance personalized medicine in cancer. While our past efforts have largely centered around the patient-specific treatment testing service, out platform, team and success advancing pharmaceutical partner assets have demonstrated that Notable itself has a proven technology stack to advance novel drug programs of its own. As such, 2018 also marked the beginning of Notable’s pipeline of therapeutic programs in various blood cancer indications.
  • is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial....
    •

Customer Relationship

  • in-licensing focused business model.

Customer Segments

  •

Key Resources

  • The most significant development has been the creation of Notable’s own pipeline of therapeutic programs in various blood cancer indications, the success of which is spurring our team buildout and upcoming fundraising efforts....
  • ** Stanford co-submitted a study showing Notable was 84% accurate in predicting responses in its clinical trial patients ** Closed 4 big pharma partners since the series A, and advanced projects with over a dozen biotechs, these are resulting in publications showing Notable predicts results of their clinical trials ** Rapid advances in drug development at Notable over past 6 months: 21 assets, in 6 subtypes of blood cancer, 15 of which we’ve filed patents on ** Mike Horowitz joins as COO after selling a pharmaceutical company he sold
    •

Channels

    •

Cost Structure

    •

Revenue Streams

    •

SWOT

Strength

  • In a mere 6 months, we have identified 21 assets, in 6 subtypes of cancer, 15 of which have been already advanced to provisional patents. Notable’s burgeoning intellectual property portfolio encompasses several different therapeutic modalities...as well as method patents on our approach to identifying these assets."
  • + Defensible: Notable Labs will use each patient’s tumor sample and test results to build a tumor bank and database of treatment outcomes. With only a few hundred patients, the company will become the largest repository of primary human brain tumor samples in the world. Notable Labs will monetize the annotated tumor bank by licensing samples and providing preclinical contract research services for pharmaceutical companies to test their novel molecules. No other company is poised to build this database, and further, no pharmaceutical company is incentivized to build such a database on their own. They are turning cancer treatment into a data problem.
    •

Weakness

  • Test
  • Test

Opportunities

  • First and foremost, it works. Early tests have already shown drug combinations that extend life in labs, and the company could technically go-to-market today — but to maximize their brand & reputation in market, they are conducted a trial with Tim Cloughesy (Director, UCLA Neuro-Oncology Program) and intend to go to market later this year or early next in Glioblastoma Multiforme brain cancer. The company was able to attract the strong investors named above because their completely unique approach to cancer treatment is already working to extend life.
  • + Business model: Notable doesn't sell cancer treatment drugs or the promise of future treatment; it sells a service to rapidly provide cancer patients with options for effective treatments that are available to them TODAY. While initially the testing service will employ a self-pay model for patients, it is expected that once the upcoming trial shows survival extension in patients insurance will reimburse for it. Notable Labs’ goal is to continuously drive down the cost of the testing service so that more patients can use the test and build up Notable Lab’s database and tumor bank.
  • Phase 2 opportunity: The company will use the findings from its proprietary database of patient treatment outcomes and empirically identified biomarkers to subgroup patients based on response to certain combinations. With data linking biomarkers to specific combination drug therapies, Notable Labs will be able to significantly de-risk the FDA-approval process, reducing the cost and time required to achieve marketing exclusivity as compared with the traditional drug development cycle.
  • Market: Notable Labs is initially focused on Glioblastoma Multiforme (GBM), the most common and deadly form of adult brain cancer. This disease — affecting roughy 50,000 new patients each year — has no known cure and an average survival of 14 months. Given the poor prognosis and the lack of established treatment options, patients, their doctors, and the FDA are receptive to repurposing existing drugs that may have anticancer effects. Notable Labs will initiate a feasibility study of its testing service for newly diagnosed GBM patients in late 2015 before launching commercially as a CLIA lab service. After proving the company’s approach in GBM, Notable Labs will pursue other high need cancer indications, such as brain metastases and their primary tumor sites, which has 200,000 newly diagnosed patients a year.

Threats

  • Besides facing the many usual risks of any startup (market, competition, execution, economy, etc), Notable Labs faces the additional risks faced by pioneering a new product offering in a highly regulated industry. Additionally, it's always possible that the company will fail to secure its next round of financing.
    •

Porter's 5 Forces

Threats of New Entry

  • They might fail to acquire the partnerships they are planning. The market might not continue to buy their products. A major competitor might emerge that kills them. They might fail to raise enough capital to get to profitability. They might never get to profitability. The market might change in such a way that they become obsolete. There are many more ways this company fails that I can't currently imagine.
  • Test
  • Test
  • Test
  • Test
  • Test
    •

Threats of Substitute Products

  • Test
  • Test
  • Test
    •

Competition
  • Test
  • Test
  • Test
    •
Bargaining Power of Customer

  • Test
  • Test
  • Test
    •

Bargaining Power of Supplier

  • Test
  • Test
  • Test
    •

PESTEL

Politic

  • Test
  • Test
  • Test
    •

Economy

  • Test
  • Test
  • Test
    •

Social

  • Test
  • Test
  • Test
    •

Technology

  • Test
  • Test
    •

Environment

  • Test
  • Test
    •

Legal

  • Test
  • Test
    •

Business Model Canvas

Value Proposition

    •

Revenue Stream

    •

Cost

    •

Key Resources

    •

Key Partners

    •

Key Activities

    •

Customer Segments

    •

Channels

    •

Customer Relationship
    •

Monopoly Characteristic

Proprietary Tech

  • Test.

Network Effect

  • Test
    •

Econ. of Scale

  • Test
    •

Branding

  • Test

7 Questions of Business

Engineering Question

  • Test

Timing

  • Test

Monopoly

  • Test

People

  • Team: Notable Labs was founded by Matt De Silva and Pete Quinzio. Matt became intimately aware of problems with the current standard of care for brain cancer patients when his father was diagnosed with GBM in October of 2013. The company was founded with the personal mission of addressing the inadequacies of the healthcare system and the lack of options it provides to patients with late-stage cancer diagnoses. Matt, Pete, and a team of scientists operate their lab in San Francisco."

Distribution

  • Test
    •

Durability

  • Test

Secret
  • Test